Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

noticia |

Elaidi R., Harbaoui A., Beuselinck B., Eymard J.-C., Bamias A., De Guillebon E., Porta C., Vano Y., Linassier C., Debruyne P.R., Gross-Goupil M., Ravaud A., Aitelhaj M., Marret G., Oudard S.

Annals of Oncology 2015 26:2 (378-385) Article Number mdu552

In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months…(vermás)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)